Seeking Alpha

Feuerstein questions Stemline's use of message board posts

  • Shares of Stemline Therapeutics (STML) are off 4% in premarket trading in the face of a rather negative article by TheStreet's Adam Feuerstein.
  • Feuerstein discusses the company's use of posts from a message board (hosted by the Leukemia and Lymphoma Society) in its investor slide deck.
  • The article questions the appropriateness of leaving out certain passages of the posts when using them in the investor presentation.
  • Feuerstein also says "a donor lymphocyte infusion" may have contributed to the complete remission of one patient being treated with SL-401, a possibility the company acknowledged as "within the realm of possibility."
  • For more on SL-401, see here.
Comments (1)
  • toosmarttofail
    , contributor
    Comments (471) | Send Message
    Nice hit piece (the original story). Seems the stock shurgged it off. That has to be a solid trading indicator (I've been long since 36).
    4 Dec 2013, 06:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: